Article Text

Download PDFPDF
Learning from errors
Incidence of CMV-HCV coinfection in renal transplant recipient
  1. Avirup Chakraborty1,
  2. Krishna Patil2,
  3. Sanjay Dasgupta2,
  4. Abhijit Tarafdar2,
  5. Sekhar Chakrabarti1,
  6. Nilanjan Chakraborty1
  1. 1Virology Department, ICMR Virus Unit, Kolkata, India
  2. 2Nephrology Department, SSKM Hospital, Kolkata, India
  1. Correspondence to Dr Nilanjan Chakraborty, nilanjanchakraborty{at}


The authors report a case of a 47-year-old cytomegalovirus (CMV) immunoglobulin G (IgG) seropositive male patient with end stage renal disease who received a live renal transplant from a CMV IgG seropositive donor. Six months post-transplantation, the patient presented with reduced renal allograft function associated with fever, severe breathlessness, new onset jaundice and pancytopenia. His CMV DNA PCR came positive. Hepatitis C virus (HCV) RNA PCR also came positive (genotype I) though anti-HCV test performed before and after transplantation was negative. The patient was treated with oral valganciclovir and showed improvement of his clinical condition and was subsequently discharged under supervised therapy. However, the patient could not be treated for HCV because of risk of renal allograft rejection. The authors suggest oral valganciclovir for management of CMV infection and proper detection and eradication of HCV before renal transplantation to avoid future complications and prolongation of allograft survival.

Statistics from


  • Competing interests None.

  • Patient consent Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.